Calcium channel blocking agents and risk of cancer in patients with coronary heart disease. Benzafibrate Infarction Prevention (BIP) Study Research Group.

Braun, S; Boyko, V; Behar, S; Reicher-Reiss, H; Laniado, S; Kaplinsky, E; Goldbourt, U

Braun, S; Boyko, V; Behar, S; Reicher-Reiss, H; Laniado, S; Kaplinsky, E; Goldbourt, U.

Affiliation

Braun S; Department of Cardiology, Tel Aviv Medical Center, Israel. braun@netvision.net.il

J Am Coll Cardiol ; 31(4): 804-8, 1998 Mar 15.

Article in En | MEDLINE | ID: mdl-9525550

Subject(s)

Calcium Channel Blockers/adverse effects; Coronary Disease/drug therapy; Neoplasms/chemically induced; Aged; Calcium Channel Blockers/therapeutic use; Cause of Death; Confidence Intervals; Diltiazem/adverse effects; Diltiazem/therapeutic use; Female; Humans; Male; Middle Aged; Nifedipine/adverse effects; Nifedipine/therapeutic use; Odds Ratio; Risk Factors; Verapamil/adverse effects; Verapamil/therapeutic use

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Calcium Channel Blockers / Coronary Disease / Neoplasms Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: J Am Coll Cardiol Year: 1998 Type: Article Affiliation country: Israel

Search on Google

XML

PubMed Links